NCT04587908View on ClinicalTrials.gov

A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]

・Treatment period：oral administration for 52 weeks, BID after meal

DRUG

Placebo [Ambulatory Cohort] only

"* Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal"

Trial Locations (5)

Unknown

A site selected by Taiho Pharmaceutical Co., Ltd., Aichi

A site selected by Taiho Pharmaceutical Co., Ltd., Fukuoka

A site selected by Taiho Pharmaceutical Co., Ltd., Hokkaido

A site selected by Taiho Pharmaceutical Co., Ltd., Osaka

A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04587908 - A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） | Biotech Hunter | Biotech Hunter